[Status of use and side effects of atovaquone for the treatment and prevention of pneumocystis pneumonia in HIV infected patients in Japan--from 1997 to 2012--The Clinical Study Group for AIDS Drugs, supported by Health and Labor Science Grants from the Ministry of Health, Labor and Welfare, Japan].

@article{Yotsumoto2013StatusOU,
  title={[Status of use and side effects of atovaquone for the treatment and prevention of pneumocystis pneumonia in HIV infected patients in Japan--from 1997 to 2012--The Clinical Study Group for AIDS Drugs, supported by Health and Labor Science Grants from the Ministry of Health, Labor and Welfare, Japan].},
  author={Mihoko Yotsumoto and Keiko Shinozawa and Yasuyuki Yamamoto and Yusuke Sekine and Katsuyuki Fukutake},
  journal={Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases},
  year={2013},
  volume={87 4},
  pages={435-40}
}
PURPOSE Atovaquone is effective and well-tolerated for the treatment of mild or moderate Pneumocystis pneumonia (PCP) and the prevention of PCP. When atovaquone was not yet approved in Japan, it was supplied by the Clinical Study Group for AIDS Drugs, which has been supported by the Japan Health Science Foundation since 1997. We investigated the status of… CONTINUE READING